Table 1.

Patient demographics

Patient number	Previous therapy	Time to metastatic disease (months) date	Date on study	Disease sites
Age 59-M (Mel 1)	Surgery/RT CNS	(36) 5/1/98	3/10/99	PET: retroperitoneal LN; M1a
Age 55-M (Mel 2)	Chemo/IL-2 IFN alpha	(24) 7/1/98	4/3/99	CT/MRI/PE : skin, LN, CNS, liver, lung ; M1c
Age 43-F (Mel 3)	Surgery	(6) 3/1/99	5/14/99	CT/PE: skin, LN, bones, and liver; M1c
Age 43-F (Mel 4)	Chemo/IL-2 IFN alpha	(82) 12/1/98	5/21/99	CT: subcarinal LN mass, pulmonary nodule; M1b
Age 44-M (Mel 5)	Chemo/IL-2 IFN alpha	(10) 12/1/98	6/26/99	CT/X-ray/PET: spleen, liver, and pulmonary nodules; M1c
Age 36-M (Mel 6)	Surgery/IL-2	(30) 12/1/98	9/1/99	CT/PE: skin nodules and LN; M1a
Age 61-F (Mel 8)	Surgery/RT Ocular	(69) 6/1/99	10/1/99	CT/PE: skin, liver, lung; M1c
Age 44-M (Mel 9)	Surgery/RT CNS cell vaccine	(10) 11/1/94	10/5/99	PE: axillary LN mass; M1a
Age 50-M (Mel 10)	Surgery	(144) 10/1/98	10/16/99	PE: femoral LN next to biopsy proven LN; M1a
Age 56-F (Mel 12)	Surgery/RT CNS	(35) 3/1/99	10/28/99	MRI/PE: skin nodule, CNS ; M1c
Age 50-M (Mel 13)	Surgery/RT CNS	(1) 5/1/99	10/29/99	MRI/CT: axillary LN and CNS; M1c
Age 43-F (Mel 15)	Surgery/ IFN alpha	(1) 11/1/99	2/16/00	PET: LN, lung and spleen; M1b
Age 73-M (Mel 16)	Chemo	(96) 1/1/00	3/2/00	CT: retroperitoneal LN, liver; M1c
Age 57-F (Mel 17)	Surgery	(40) 2/1/00	3/15/00	CT/PET: lung nodule; M1b
Age 69-F (Mel 18)	Surgery for vulvar melanoma	(3) 2/1/00	3/18/00	CT/PET/PE: pericardial nodule and vaginal wall; M1b
Age 67-M (Mel 19)	RT	(6) 11/1/99	3/29/00	PET/PE: parotid nodule; M1a
Age 40-F (Mel 20)	Surgery	(44) 12/1/99	5/4/00	PET/PE: LN, liver and chest wall; M1c
Age 66-M (Mel 21)	Surgery	(1) 4/1/00	5/9/00	Hepatic, lymph node (M1c)

Patient age, gender, previous therapy, time to metastatic disease and to study entry as well as disease sites on entry